

Subject Index

- AAV** (adeno-associated virus) in gene therapy, 79-88, 105-11
- AAV-2** (wild-type adeno-associated virus), 82
- ABMT.** *See* Autologous bone marrow transplantation
- Accelerated hematologic recovery.** *See* Early engraftment
- Aclarubicin**, 118
- Actins**, muscle, 71
- Acute lymphocytic leukemia.** *See* ALL
- Acute lymphoid leukemia.** *See* ALL
- Acute myeloblastic leukemia**, 207
- Acute myelocytic leukemia.** *See* AML
- Acute myelogenous leukemia.** *See* AML
- Acute myeloid leukemia.** *See* AML
- ADA deficiency**, 17-18
- Adeno-associated virus.** *See* AAV
- Adenosine deaminase deficiency**, 81
- Adoptive transfer studies**, 190, 195-96
- Agammaglobulinemia**, 9, 11, 14
- AIDS**, 81, 87
- ALL**, 35-36
- gene therapy in, 106
 - preparative regimens in, 2, 4
 - purging in, 263, 269-74
 - stem cell transplantation in, 262-63, 265, 267-75, 278-82
- Allogeneic bone marrow transplantation**
- autologous BMT compared to, 276-83
 - enhancing graft-versus-malignancy effect in, 203-9
 - ex vivo* expanded hematopoietic cells in, 102, 103
 - Fas and perforin pathways in, 368-69
 - GM-CSF or G-CSF after, 59-61
 - HGF and, 54
 - perforin studies in, 339-43, 368-69
 - sources of stem cells in, 54
 - stem cell transplantation in, 262-63
 - T-cell depletion of stem-cell grafts for, 102
- Allograft rejection.** *See* GVHD; GVHR; organ transplantation
- Allosensitization**, 171
- Aminopterin**, 130
- AML**, 36
- ABMT in, 74
 - gene therapy in, 106
 - preparative regimens in, 2-4
 - PBSC in, 118, 272-76
 - purged vs. unpurged marrow in, 263, 269-74
 - stem cell transplantation in, 262-63, 265-83
- Anaphylactic shock**, plasmacytosis and, 8
- Anemia**
- aplastic, 2, 16-18, 37, 106, 149
 - Fanconi, 84, 105, 106
- Anthracycline**, 289-90, 292, 294, 299, 302
- Antibiotics**, HGFs with, 64
- Antibodies**
- anti-CD34, control cells for, 370-72
 - HAT, 135, 138
 - monoclonal (mAbs), 42, 43, 47, 135-38, 142, 146
 - in breast-cancer MRD, 248
 - varieties of, 178, 180
 - plasma cells and, 8-9
 - Stro-1, 71, 74
 - thymus and, 11-12, 14
- Antigen-presenting cells (APC)**, 204
- Antigens**
- CD34 control cells and, 370-72
 - Class II
 - in liver experiment, 172
 - in syngeneic/autologous GVHD, 189-98
 - in VBM study, 361-62 - Factor-VIII-associated, 71
 - Hermes, 179
 - leukemia-specific, 206
 - myeloid differentiation surface, 206
 - tissue-restricted, 206
 - in X-linked SCID case, 376
- Antilymphocyte globulin**, 346
- Antithymocyte globulin (ATG)**, 2, 3, 130, 136, 152
- Antithymocyte serum (ATS)**, 152
- APC** (antigen-presenting cells), 204
- Apheresis**, 45, 48-49, 53
- Aplasia**, PBSC transplantation and, 116, 120-21
- Apoptosis**, 20, 205, 216-24, 246, 253
- mafosfamide induction of, 274
- ARA-C**, 118, 280, 306
- Argon ion laser**, 43
- Aspergillosis**, 208
- ATG.** *See* Antithymocyte globulin
- ATS** (antithymocyte serum), 152
- Autoaggression syndrome**, 189-92, 195-96, 198
- Autografting**
- PBSC, 272-76
 - worldwide review of, 268-69
- Autologous bone marrow transplantation**
- allogeneic BMT compared to, 276-83

- ex vivo* expanded cells in, 101-2
 GM-CSF or G-CSF after, 54-57
 growing use of, 37-38
 HGF and, 54-57
 high rate of tumor recurrence in, 192-94
 LTMC cells in, 74
 malignant cells in, 38-39
 mobilization of PBSC for, 116-26
 PBSC and HGF alternative to, 58-59
 residual leukemic cells in, 262-63
 sources of stem cells in, 54
 stem-cell transplantation in, 262-63
 using purging by mafosfamide, 264-68
 tumor cell contamination in, 100-101
 Azathioprine, 150, 152, 154
 kidney recipients treated with, 167
- B**ACT-derived preparative regimens, 4
 BAL fluid, leukocytes in, 182-83
 BAVC preparative regimens, 4
 B-B10, 137
 B cells, 12, 14, 18, 71, 92
 BTK gene and, 10-11
 lymphoproliferative disorders of, 138
 progenitors of, 44, 50
 tumors of, MRD detection of, 244
 BEAM preparative regimens, 4
 BEC protocol, 307, 309-10
 BFU-E, 71, 107, 110
 Biotin/streptavidin affinity separation, 43
 Bisantrene, 299
 Blood-brain barrier, busulfan's crossing of, 3
 Blanket cells, 71
 BMSC (bone-marrow stem cells). *See* Stem cells
 Breast cancer
 autologous BMT in, 38, 39
 CY effects in women with, 239
 detection of MRD in, 242, 245, 248-50, 292
 evaluation in, 289
 high-dose chemotherapy in, 288-302, 316
 induction of autologous GVHD in, 198
 mortality in, 288
 PBSC transplantation in, 120, 291, 294-95, 301
 Bronchoalveolar lavage (BAL) fluid, leukocytes in, 182-83
BTK gene, 10
 BUCY regimen, 290-93, 316, 318, 320, 321, 323-25, 327-29, 331-34
 Bursa of Fabricius, removal of, 11-15
 Busulfan (BU)
 in high-dose chemotherapy, 290-91, 316, 318
 in preparative regimens, 3-4, 36-37, 237-40
- C**AF (fluorouracil), 298
 Calciparin, 352
 Carboplatin, 239, 290-91, 306-7, 316, 318
 Carcinoma, 252
 Cardiolipin, 380
 Carmustine (BCNU), 4, 239, 299, 306-7, 310, 311
 Cattle, chimerism in, 173
 CBV preparative regimens, 4
 CD3 cells, 107, 144, 146, 207, 216, 217, 223, 353, 368
 CD4 cells, 141, 143-47, 183, 189-93, 196-97, 204, 205, 208, 215-17, 353, 355, 359, 374
 in bright cells' crossing of MHC barrier, 379
 in HIV-1, 219-21, 223-24
 CD5 cells, 138
 CD7 cells, 43, 44, 50
 CD8 cells, 143-44, 147, 189-94, 196-97, 204, 205, 216-17, 340, 353, 356, 359, 374, 379
 in HIV-1, 219-21, 223
 selective depletion of, 208
 CD10 cells, 44, 71, 72, 75, 92, 100
 CD13 cells, 206
 CD18 cells, 179
 CD19 cells, 43, 44, 47, 50-51, 92, 93
 CD20 cells, 92
 CD25 cells, 137
 CD29 cells, 218-19, 222, 223
 CD30 cells, 253
 CD33 cells, 206
 CD34 cells, 42-51, 58, 63, 72, 75, 83-84, 91-95, 106-7, 110, 118, 138, 180-81, 215, 319-20, 333, 334, 358
 control cells to standardize enumeration of, 370-72
 as markers in purging, 247-48
 number of, for successful transplantation, 42
 CD34-FITC, 361
 CD38 cells, 47, 93-94, 95, 218-20, 223, 358
 CD40 cells, 253
 CD43 cells, 92
 CD44 cells, 73, 75, 179, 182
 CD45 cells, 71, 72, 75, 146
 CD45RA cells, 43, 44, 47, 51, 146, 215, 218-20, 222, 223
 CD45RO cells, 146, 215, 218-20, 222, 223
 CD54 cells, 179
 CD62E cells, 178
 CD62L cells, 178
 CD62P cells, 178
 CD71 cells, 379
 Cellular engineering, 15, 18

- Centrifuges
 - continuous-flow, 38
 - density-separation by, 43
 - Shandon cytopsin, 248
- Ceprate SC, 43
- Cervical cancer, 252
- CFU (colony-forming units), 50, 91, 253
- CFU-C cells, 58
- CFU-E cells, 91
- CFU-G cells, 91
- CFU-GEMM cells, 58, 64, 107-10, 253
- CFU-GM cells, 64, 71, 107-10, 119, 269, 328, 331, 333, 334
 - mafosfamide doses adjusted to, 264-65
- Chemopurging, 246
- Chemotactic factor production, 378
- Chemotaxis model of PBSC mobilization, 125
- Chemotherapy
 - ABMT compared to allogeneic BMT with, 280-82
 - BMT with TBI and, 2, 35-37
 - contamination of marrow in, 38-39
 - cord blood transplantation after, 105
 - high-dose
 - in breast cancer, 288-302, 316
 - in Hodgkin's disease, 305-11
 - regimens in, 290-92, 316, 318
 - usefulness of, 315-16
 - in leukemias, 35-37, 315
 - PBSC and HGF alternative to, 58-59
 - in PBSC mobilization, 117-18, 122
 - tandem (double induction), 263
- Chicken, removal studies in, 11-15
- Children
 - ABMT vs. allogeneic BMT in, 277, 278, 282
 - ABMT with unpurged marrow in, 270
 - ALL in, 35-36
 - AML in, 36
 - born without thymus or parathyroid glands, 14
 - busulfan regimen in, 238
 - CML in, 106
 - role of thymus in, 215
 - SCID in, 17-18
- Chimerism
 - fully tolerant BM, 21
 - human-fetal sheep, 93, 94
 - mixed, 21-22
 - in mouse study, 355-56, 359
 - in organ transplantation, 22-23, 167-74, 361
 - spontaneous, 174
- Chronic myelogenous leukemia. *See* CML
- Chronic myeloid leukemia. *See* CML
- Chymopapain, 370-72
- Cisplatin, 118, 239, 299
- CK 19 (cytokeratin 19), 250, 251
- Clonogenic assays, 42, 43, 84
- CMF (5-fluorouracil), 20, 118, 298
- CML, 35, 36-37, 39, 106, 116-17, 134, 206, 207, 35, 130-31, 134-35, 138
 - detection of MRD in, 242-43, 246-47
 - juvenile, 106
- CMV. *See* cytomegalovirus
- Cobblestone areas, 71
- Collagen, Type I, 172
- Colon cancer, 252
- Concanavalin, 144, 376
- Conditioning regimens. *See* Preparative regimens
- Cord blood stem cells, 79
 - cryopreservation of, 38, 106
 - ex vivo* expanded, clinical use of, 102, 103
 - in FACS analysis, 42-43, 45, 50-51
 - gene therapy and, 105-11
 - GVHD and, 38, 138
 - in reconstitution of mice, 351
- Coronary vascular disease, stem cell-enriched BM vs., 380
- Corticotrophin-releasing factor, 150, 153, 154
- COS-7 cells, 180
- Cost effectiveness of GM-CSF vs. G-CSF, 55-57, 60
- Cost of dose-intensive therapy, 311
- Coulter EPICS XL flow cytometer, 361
- C-reactive protein, 9
- Cryopreservation, 34, 38, 106
- CsA. *See* Cyclosporine
- CTL. *See* Cytotoxic assay
- CTLA4Ig, 138, 169
- CWR-βGal, 83-84
- CY. *See* Cyclophosphamide
- Cyclophosphamide (CY)
 - derivatives of, 263
 - as immunosuppressive agent, 149-50, 152, 193
 - in PBSC mobilization, 118, 122
 - in preparative regimens, 2-4, 36-37, 237, 238-39
- Cyclosporine (CSP, CsA)
 - antitumor activity in GVHD induced by, 189-92, 196-98
 - in GVHD, 130, 131, 134-36, 138, 339, 374
 - as immunosuppressive agent, 150-55
 - in preparative regimen, 2
- Cytarabin, 307
- Cytarabine, 4
- Cytoablation, 167, 168, 173, 346
- Cytofluorometric analysis, 352-54
- Cytokeratin 19 (CK 19), 250, 251
- Cytokines

- antitumor activity of GVHD modulated by, 198
 better methods of using, 311
 expansion of progenitor cells by, 99-101
 in GVHD, 131, 227-33
 in Hodgkin's disease treatment, 307
 matrix-bound, in stroma, 73
 in retroviral transduction, 81
 in stem cell transplantation, 53-64
 in *in vitro* growth of stem cells, 40
 Cytokine storm, 131, 227-28, 339
 Cytomegalovirus (CMV), 38, 82, 107, 108, 208, 307
 Cytometry, multicolor flow, 92
 Cytosine arabinoside (ARAC), 149-50, 263
 Cytotoxic assay (CTL), 352, 357, 359
- D**aunorubicin (DNR), 118, 280
 Defenseless recipient experiments, 165-67
 Dendritic cells, as tolerogenic, 171-73
 Deoxynucleotidyl transferase, 92, 94
 15-Deoxyspergualin (DSG), 150
 LF 08-0299 analog of, 373
- Diabetes
 graft-survival statistics for, 174
 islet-cell transplantation for, 361
- DiGeorge syndrome, 14, 15
 Dimethylmyleran, 20
 Dimethylsulfoxide, 264
 DMBC (donor bone marrow derived cells),
 in organ allografts, 346-49
- DNA synthesis, 83, 86
 DNR. *See* Daunorubicin
- Dogs
 BMT in, 15, 34-35
 cytoablation not used in BM engraftment
 of, 346
 GVHD prevention study in, 149-61
 Donor bone marrow derived cells. *See* DMBC
- Doxorubicin, 118, 298, 299
 DPBS (Dulbecco's phosphate-buffered saline solution), 320
 DREG, 178
 DR-PE, 361
 DSG. *See* 15-Deoxyspergualin
 Dulbecco's phosphate-buffered saline solution (DPBS), 320
- E**arly engraftment with PBSC, 120-23
 EBV-LCL, 144, 147
 EGF, 179
 ELAM-1, 178
 Endocarditis, bacterial, 8
 Endothelial cells
 CD34 and, 92-93, 180
 lymphocyte migration and, 177
- Endotoxin
 Il-1 amplification of, 227-28
 NO levels and, 232
- Enzymes
 BMT in deficiencies of, 17-18
 primary and secondary granule, 206
 EORTC-GIMEMA-AML8A trial, 280-82
 Epo, 107-10
 Erythropoiesis, 71
 Erythropoietin, 58, 61-63, 107
Escherichia coli, 228
 Etoposide, 4, 118, 122, 263, 306-7, 316, 318
 in breast-cancer treatment, 290-91
- "F**acilitating" cells, 22
 FACS (flow cytometric) analysis, 42-51,
 209, 347, 358, 361-62, 380
 FACS Star Plus Cell Sorter, 43, 107
 Factor VIII, 71
 Factor IX, 71
 Fas, 20, 205, 340
 in allogeneic resistance to BM, 368-69
 F4/80 cells, 74
 Fetal bovine serum, 107, 320
 Fibroblasts, dermal, 228
 Ficoll-Hypaque, 106, 352
 Ficoll-Paque, 43
 FLX protein, 74
 FK506 (tacrolimus), 135, 138, 374
 as immunosuppressive agent, 150,
 153-55, 173, 174, 339
 in rat chimerism studies, 170
 Flow cytometric (FACS) analysis, 42-51,
 209, 347, 358, 361-62, 380
 Fluorouracil (CAF), 298
 5-Fluorouracil (CMF), 20, 118, 298
 Freezer, Nicool 316 biologic, 264-65
 Fucoidin, 179
- B**-Galactosidase, 83, 84, 107-10
 X-galactoside, 108
 Gambro bags, 264-65
 Gamma globulin, 8-9, 228
 Ganciclovir, 38
 Gastrointestinal tract
 cancer of, 252
 in cytokine production in GVHD, 227-28
 in FK506 treatment, 170
 in GVHD, 132, 133, 136
 response to TNF- α by, 231
 Gaucher's diseases, 81
 G-CSF (granulocyte-colony-stimulating factor), 38, 43, 50, 54-63, 118, 121, 264
 in hematopoiesis after stem-cell transplantation, 319-22, 324-27, 329,
 331-36
 Gene marking, 263

Genes

- BTK*, 10
- LacZ*, 107-11
- neomycin-resistance, 263, 271
- PLAP, 85-86

Gene therapy

- adeno-associated viral vectors in, 79-88, 105-11
- perfusion expansion infection cultures in, 101
- stem cell, 101

Genetic diseases

- allogeneic BMT in, 37
- hematopoietic stem cell and, 40
- preparative regimen in, 4

Gentamycin, 364

Glomerulonephritis, stem cell-enriched BM to prevent, 380

Glucocorticoids, in GVHD, 136

Glucose oxydase method, 249

GlyCAM-1, 179-80

Glycophorin A. *See* GPA

Glycosaminoglycans, 73

Glycosylations, 181

GM-CFU cells. *See* CFU-GM cells

GM-CSF (granulocyte-macrophage colony-stimulating factor), 38, 43, 50, 54-64, 73, 107, 118, 121, 143-47, 182, 230, 263, 318-20

- in hematopoiesis after stem-cell transplantation, 319-22, 326-29, 331-34

GMP-140, 178

GPA (glycophorin A), 43, 50, 72

Gr-1 cells, 379

Graft-versus-leukemia (GVL), 39, 136, 158, 203-6

- in allogeneic BMT, 262, 263
- new ways to manipulate, 207-9
- separation of GVHD from, 264

Graft-versus-malignancy effect in allogeneic transplants, 203-9

Granulocyte-colony-stimulating factor. *See* G-CSFGranulocyte-macrophage colony-stimulating factor. *See* GM-CSF

Granulopoiesis, 71, 73, 315, 316, 325-27, 335-36

Growth factors

- fibroblast, 63
- hematopoietic. *See* HGF
- hepatocyte, 63
- in PBSC mobilization, 118-19, 122-23
- platelet-derived. *See* PDGF
- transforming (TGF- β), 63

Gut. *See* gastrointestinal tract

GVHD (graft-versus-host-disease), 130-39 in allogeneic BMT, 262

clinical manifestations of, 131-33
in cord blood transplantation, 106
deliberately induced, attempted reversal of, 157-58

gamma globulin in reduction of, 228
human autologous, 196-98
inflammatory response in, 227-28
methotrexate vs., 35, 130-31, 134-35, 138
perforin in development of, 339-43
prevention of, 130-39

- bowel decontamination, 227-28
- histocompatibility matching, 149
- immunosuppressive drugs, 149-61
- LF 08-0299 for, 373-75
- in newborn-blood study, 351-59
- perforin and, 339-43, 366-67
- various methods, 339

prophylaxis for, 133-35

requirements for development of, 130
residual malignant cells in, 158

in SCID cases, 16-17, 145

separation of GVL from, 264

syngeneic/autologous, antitumor activity of, 189-99

target tissues for, 204

T-cell depletion in, 136

T-cell subsets associated with, 142-43, 145, 146

tolerance in, 39

treatment for, 136-38

GVHR (graft-versus-host reaction)

- history of thinking on, 34-35
- new ways to manipulate, 207-9
- T-cell purging and, 19-20

GVL. *See* Graft-versus-leukemia**H***aemophilus influenzae*, 9

Hamsters, thymectomy in, 12

Hansenula hostii, 179

Haploidentical BMT, 20

functional T-cell depletion in, 208

T-cell immune reconstitution after, 376-77

Harvesting. *See* Purging

H-CAM, 179

Heart

in children born without thymus or parathyroid glands, 14

CY dose and, 239

stem cell-enriched BM vs. disease of, 380

transplantation of

- chimerism in, 22, 170
- graft-survival statistics, 174

Hematolymphoid organ, in GVHD, 133

Hematopoiesis

and detection of MRD, 243

ex vivo, 99-103

origin of, 47, 70

- relative contributions of various factors in, 315-37
- growth factors, 315, 318-19, 326-27
- marrow microenvironment, 315, 320-25
- stem cells, 315, 319-20, 328-33
- stromal regulation of, 72-74
- See also* Stem cells—hematopoietic
- Hematopoietic chimerism, 17
- Hematopoietic progenitor and stem cells. *See* Stem cells
- Hemoglobinopathies, 79
- HEPA-filtered air-handling systems, 307
- Heparin, 364
- HEPES, 364
- Herpes, in Hodgkin's disease, 9
- Herpes simplex virus (HSV-1), 81, 83
- HEV (high endothelial venules), 178-82, 184
- HGF (hematopoietic growth factors), 38, 53-64
- in hematopoiesis after stem-cell transplantation, 316-18, 335-36
- multiple, 99-100
- High endothelial venules. *See* HEV
- Histocompatibility matching, 149
- History of BMT, 34-35
- HIV-1 (human immunodeficiency virus), 82-83, 213
- T-cell apoptosis in, 219-23
- HLA (human leukocyte antigen)
- in cytoablation before transplantation, 167
- in cytokine storm, 227
- incompatibility of, 143-47
- HLA-DR, 72, 75, 145, 218-20, 223, 362, 371
- HLA-identical siblings, 35-37, 39, 150, 153, 204, 262
- ABMT vs. allogeneic transplantation in, 276-83
- Hodgkin's disease, 9, 55, 55, 196
- dose-intensive therapy for, 305-11
- Homing, 178
- Hospital discharge criteria, 54-55
- HPCA2, 43, 371
- HRL-3, 178
- Human immunodeficiency virus. *See* HIV-1
- Human serum albumin, 364
- Hunter's syndrome, 106
- Hurler's syndrome, 106
- Hyaluronic acid, 73
- Hybridoma, 91
- 4-Hydroperoxycyclophosphamide (4-HC), 263, 270
- Hyperglobulinemia, 8
- Hypogammaglobulinemia, 376
- I**CE regimen, 290-93, 299, 300, 302, 316, 318, 320-24, 326-29, 331-34
- Idarubicin, 263
- IFN. *See* Interferon
- Ifosfamide, 118, 290-91, 316, 318
- Immu-133, 371
- Immune amnesia, 224
- Immune deficiency, 79, 106
- lymphoid system deficiency and, 14
- mechanisms of, 213
- preparative regimen in, 4
- Immune memory, 213-15, 219, 221-24
- Immune system
- organization and development of, 8-23
- two-component cellular definition of, 10
- Integrins, 73, 75
- γ -interferon, 63, 99, 131, 141-47
- antitumor activity of GVHD increased by, 194-98
- CD4 cells' inhibition of leukemia through, 205
- GVHD role of, 229-30
- NO levels and, 232-33
- Interleukin-1 (IL-1), 63, 131, 135, 138, 204
- in cytokine storm, 227-28
- GVHD role of, 231-32
- NO levels and, 232-33
- Interleukin-2 (IL-2), 131, 135, 137, 141-45, 147, 194, 195, 198, 204, 208, 227, 264, 339
- as primary cytokine in GVHD, 228-29
- Interleukin-3 (IL-3), 58, 61, 107, 108, 110, 118, 230
- Interleukin-4 (IL-4), 141, 142, 144, 147, 227, 230
- Interleukin-5 (IL-5), 141, 142, 144, 147
- interleukin-6 (IL-6), 61, 63, 141, 198
- GVHD role of, 232
- Interleukin-7 (IL-7), 72
- Interleukin-8 (IL-8), 72
- Interleukin-10 (IL-10), 141, 144-47, 227, 230
- Interleukin-11 (IL-11), 63, 72
- Interleukin-12 (IL-12), 63, 141
- Interleukin-13 (IL-13), 63
- Interleukin-15 (IL-15), 198
- Inverted terminal repeats (ITR), 81
- Iscove's medium, 320
- Islet-cell transplantation, 361
- Isoptic cesium chloride, 82
- J**apan, comparative analysis of BMT from, 203-4
- K**aplan-Meier estimates, 36, 37, 281
- Karnovsky status, 134-35
- Karyotyping, 168, 376
- Keratinocytes, 228
- KG1a cells, 180, 370-72
- Kidney

- stem cell-enriched BM vs. disease of, 380
- transplantation of
 - chimerism in, 22, 167, 170
 - graft-survival statistics, 174, 345
 - multiple BM infusions, 345-46
- Kinase, tyrosine, 10
- Kinase C, 92, 93
- Kit legend, 61
- L**
 - LACE** preparative regimens, 4
 - LacZ* gene, 107-11
 - LAK cell therapy, 102
 - LAM, 178, 180
 - Laminin, 71
 - Lectin-purging techniques, 19
 - Leflunomide, 138
 - Leishmania major*, 141-42
 - Leu8, 178, 181
 - Leukaphereses, 263, 319
 - Leukemia
 - acute, 134
 - stem-cell transplantation in, 262-83
 - acute lymphoid (lymphocytic). *See* ALL
 - acute myeloblastic, 207
 - acute myeloid (myelogenous; myelocytic).
See AML
 - CD4 cells' inhibition of, 205
 - chemotherapy-resistant high risk, 19-20
 - chronic myeloid (myelogenous). *See* CML
 - detection of MRD in, 242, 243-46
 - drug-resistant, 18
 - high-dose chemotherapy in, 315
 - juvenile chronic myelogenous, 106
 - lymphoblastic, 106, 134, 246
 - malignant cells in treatment of, 38-39
 - murine, 82
 - neonatal thymectomy and, 12
 - T-cell responses to, 204-5
 - Leukemia antigens, 206
 - Leukemia-specific antigens, 206
 - Leukephereses, 102
 - Leukocytes
 - BMT for abnormalities of, 18
 - in chimerism, 167-69, 171
 - migration of
 - after organ transplantation, 171
 - See also* Lymphocytes
 - passenger, 173
 - Leukosialin, 92
 - Leu-Leu-OME, 158-61
 - Lewis organs, 169
 - LF 08-0299, 373-75
 - LFA-1, 179, 182
 - Lineage-negative cells, in crossing MHC barrier, 379
 - Lipopolysaccharide, 232-33
 - Liver
 - in GVHD, 132-33, 136
 - response to TNF- α by, 231
 - transplantation of
 - chimerism in, 22, 167, 170-73
 - DBMC study, 346-49
 - fetal liver, 19, 116, 138, 146
 - graft-survival statistics, 174
 - venoocclusive disease of. *See* VOD
 - Local release model of PBSC mobilization, 124
 - Long terminal repeats (LTR), 80-81, 84
 - Long-term marrow cultures. *See* LTMCs
 - LTCIC expansion, 103
 - LTMCs (long-term marrow cultures)
 - in autologous BMT, 74
 - hematopoietic environment in, 71-72, 84
 - Lungs
 - cancer of, 253
 - detection of MRD in, 242, 252
 - transplantation of, graft-survival statistics, 174
 - Lymph nodes
 - in FK506 treatment, 170
 - migration of lymphocytes to, 177-78, 181-82
 - phenotype of cells of, 353
 - Lymphocyte-HEV-adherence assay, 179
 - Lymphocytes
 - migration of, after BMT, 177-84
 - peripheral blood (PBL), 180
 - recirculation of, 177-78
 - thoracic duct (TDL), 180
 - Lymphocytic choriomeningitis virus, 340
 - Lymphohematopoietic malignancies, 198
 - Lymphohematopoietic stem cells, 93, 94
 - Lymphokines, recombinant, 195
 - Lymphoma
 - Burkin's, 244
 - detection of MRD in, 242, 243-46
 - follicular, 244, 252-53
 - high-dose chemotherapy in, 315
 - low grade, 252-53
 - non-Hodgkin's, 55, 196, 198, 251-53, 300
 - PBSC transplantation in, 120
 - preparative regimens in, 4
 - stromal cells and, 253-54
 - virus-associated, 243
 - Lysis II software, 43
 - Lysosomal storage disorders, 79
- M**
 - MABs.** *See* Antibodies—monoclonal
 - Mac-1 cells, 71, 72, 74, 75, 379
 - Macrophage inflammatory protein-1- α (MIP-1 α), 63, 230
 - Macrophages, 71-72, 228
 - Mafosfamide, 263, 264-68, 274, 275
 - Major histocompatibility. *See* MHC

- M-AMSA, 280
Mannose-6-phosphate, 179
Matched unrelated donors (MUD), ABMT
vs. allogeneic BMT with, 278-80
M-CSF, 63, 73
MECA-79, 179
MECA-325, 181
MEL-14, 178
Melanoma, 252
Membrane adhesion molecules, lymphocyte
migration and, 177-81
6-Mercaptopurine, 150, 152
Metabolic diseases, 79
Methotrexate (MTX)
as immunosuppressive agent, 150-55
vs. GVHD, 35, 130-31, 134-35, 138
in PBSC mobilization, 118
Methylcellulose, 320, 361
Methylprednisolone, 152
mHA. *See* Minor histocompatibility
MHC (major histocompatibility)
class I, 206
class II, 145, 146, 189-98, 205
GVHD induction across barriers of, 205,
339-43
lineage-negative cells in crossing barrier
of, 379
in preparative regime for GVHD, 134
siblings matched for, 18, 131
Mice
ABMT purging study in ALL, 274
autoimmune-prone, preventing coronary
vascular disease in, 380
CD34 in, 92
cell-migration experiment in, 171-73
donor experiments with, 18-21
in Fas study, 368-69
GVHD experiments with, 130
heart chimerism experiment in, 171
human blood cord cells in, 106
IFN- γ prevention of GVHD in, 229
LF 08-0299 study in, 373-75
liver chimerism experiment in, 171
mafosfamide studies in, 274
monoclonal antibodies in, 178
murine leukemia virus in, 82
newborn blood for donor cells in, 351-59
in perforin studies, 340-43, 366-67,
368-69
T-cell subsets in, 141-47, 190
thymectomy in, 12-13
Microscopy, 71, 92
Migration of lymphocytes after BMT, 177-
84
Minimal residual disease. *See* MRD
Minitransplant models, 167
Minor histocompatibility, peptides and, 131
Minor histocompatibility antigens (mHA),
204, 206
MIP-1- α (macrophage inflammatory protein-
1- α), 63, 230
Mitoxantrone, 263, 290-91, 299, 306-7,
316, 318
MITT regimen, 290-93, 316, 318, 320, 321,
323-25, 327-29, 331-34
Mixed lymphocyte reaction. *See* MLR
MLR (mixed lymphocyte reaction),
165-67, 352
Morphine, 307
MRD (minimal residual disease), detection
of, 242-55
in metastatic breast cancer, 292, 301
MTX. *See* Methotrexate
Mucinitis, 53
MUD. *See* Matched unrelated donors
My10 cells, 91
Mycophenolic acid, 138
Myelodysplasia, 106, 207
Myeloid clonogenic cells. *See* CFU
Myeloma, 117, 243, 252, 253, 371
CRL 1662, 195
detection of MRD in, 243-46
multiple, 9, 38, 207
Myeloprotectants, 63
Nadir rescue, non-transplant, 102
Nadir sepsis, 307
Natural killer cells (NK), 92, 131, 204,
340, 368
leukemia responses of, 205-6
NBB. *See* Newborn blood
Neomycin-resistance gene, 263, 271
Neuraminidase, 370
Neuroblastoma, 106, 252
Neutropenia, 8, 53
Neutrophil count as discharge criterion, 54,
55
Newborn blood (NBB), in mouse transplanta-
tion study, 351-59
Nicol 316 biologic freezer, 264-65
Nitric oxide (NO), 232-33
NO. *See* Nitric oxide
Non-stem cells
listing of, 120
in PBSC mobilization, 120
Novantrone. *See* Mitoxantrone
Nycoprep, 43
OKT3, 137
Oligonucleotides, 243, 246
One-way paradigm, 165-67, 173
Opposite sex donors, BMT with, 169
Organ transplantation
BMT and, 23

- chimerism in, 22-23, 167-74
multiple BM infusions in, 345-49
tolerance in, 39
two-way paradigm in, 167-74
- Osteoblasts, 22
- Osteopetrosis, 4
- Ovarian cancer, 252
- Overcrowding model of PBSC mobilization, 124-25
- Oxylophosphamide, 307
- P**
- Paclitaxel, 290-91
- PADGEM, 178
- PAINT-A-GATE software, 43
- Pancreas, transplantation of
in diabetics, 174
fetal, 146-47
- Paracortical regions, 10
- Paraformaldehyde, 370-72
- Parathyroid glands, children born without, 14
- Pasteurella haemolytica*, 370
- PBSC (peripheral blood stem cells)
better methods of using, 311
in breast-cancer transplantation, 120, 291, 294-95, 301
CD34 threshold number for, 42
in hematopoiesis after transplantation, 315, 319-20, 323, 324, 328-36
mobilization of, 38
advantages of, 119-21
for autologous BMT, 116-26
chemotherapy-based vs. growth factor-based, 117-19
GVHD after, 161
with HGFs, 58-59
methods, 121-23
theoretical models, 123-25
- PCR (polymerase chain reaction), 39, 145, 168
detection of MRD by, 243-52, 254, 292, 301-2
- PDGF (platelet-derived growth factor), 72
- Peanut and soybean agglutination, 19, 376
- Pediatrics. *See* Children
- Pentapeptide, 63
- Peptide differences, 131
- Perforin, 205
in allogeneic resistance to BM, 368-69
in GVHD development, 339-43
T cells deficient in, acute GVHD from, 366-67
- Perfusion-based hematopoietic expansion, 101, 103
- Peripheral blood lymphocytes (PBL), 180
- Peripheral blood stem cells. *See* PBSC
- Phenotype characterization, 352, 353
- Phenytoin, 9
- Phosphoglycoprotein, 93
- Phosphomannan monoester (PPME), 179
- Photopheresis, extracorporeal, 139
- Phycocerythrin, 320, 371
- Phytohemagglutinin, 38, 197, 376
- Placenta derived cells, 116
- Placental alkaline phosphatase gene (PLAP), 85-86
- PLAP (placental alkaline phosphatase gene), 85-86
- Plasmacytosis, 8
- Platelets
abnormalities of, 18
delayed recovery of, 59, 61
- Pneumococci*, 9
- Pneumocystis carinii*, 307
- Pokeweed, 376
- Polymerase chain reaction. *See* PCR
- PPME (phosphomannan monoester), 179
- Precursor cells. *See* Stem cells
- Prednisone
in GVHD, 131, 134-35
immunosuppression by, 173, 174
kidney recipients treated with, 167
- Preparative regimens
in breast cancer, 290-91
chemotherapy vs. chemoradiotherapy, 1-7
in CML, 36-37
GVHD and, 134
pharmacology of, 237-40
for retrovirus-mediated gene therapy, 81
- Primates, donor-specific graft acceptance in, 346
- Procarbazine, 149-50, 152
- Progenitor cells. *See* Stem cells
- Prostate, cancer of, 252
- PSC (peripheral stem cells), grafts of, 216, 218
- Pseudomonas aeruginosa*, 9
- Purging (harvesting), 18-22, 102, 243, 246-48
in ALL compared to AML, 263, 269-74
in AML studies, compared to not purging, 268-70, 273
in breast cancer, 291-92
in cell-suspension method, 346-47
in vivo, 263
- Purification of stem cells, 91-95
- Q**
- QEnd 10, 371
- R**
- Rabbits, thymectomy in, 12
- Rapamycin, 138, 156, 157
- Rats
gene transfer in, 83
monoclonal antibodies in, 178

- syngeneic GVHD experiments in, 189-90, 195-96
- thymectomy in, 12
- tolerance induction in, 169-70
- Regimens. *See* Preparative regimens
- Retroviral vectors, 80-81, 109, 111
- Rheumatic fever, 8
- RNA
- PCR analysis, 84
 - polymerase II and III, 82
 - transgene-encoded, transcription of, 85
- Rous sarcoma, 82, 83
- RPMI solution, 346, 364
- S**alvage therapy (sensitive relapse), 302, 306-7, 315
- Sargramostim. *See* GM-CSF
- SCID (severe combined immunodeficiency), 15-19
- cord-blood transplantation in, 358
 - in transplantation-tolerance study, 143-47
 - X-linked, T-cell immune reconstitution in, 376-77
- SDS-PAGE analysis, 178
- L-selectin, 92, 178-82
- Sensitive relapse (salvage therapy), 302, 306-7, 315
- Serum IgG immunoglobulin. *See* Gamma globulin
- Serum sickness, 8
- Sgp50, 179
- Sgp90, 179-80
- Sheep RBC rosetting, 376
- Sialic acids, 92, 179
- Sialomucins, 92, 179
- Siblings
- MHC-matched, 18, 131
 - minor histocompatibility differences in, 131
- See also* HLA-identical siblings; twins
- Skin
- cytokines from endotoxin on, 228
 - in GVHD, 131-32, 136, 139
 - lymphocytic eruptions on, 183-84
 - response to TNF- α by, 231
- SLF. *See* Stem cell factor
- Southern analysis, 83, 242
- Soybean agglutination, 19, 376
- Spleen
- in allogeneic resistance study, 368-69
 - in FK506 treatment, 170
 - lymphocytes in, 13
 - in NBB mouse study, 356-57
 - stem cells' migration to, 378
- Split tolerance, 170
- Statistical methods, 254, 307-8, 320, 347-48
- Steel factor. *See* Stem cell factor
- Stem cell factor (steel factor; SLF), 61, 72, 107, 108, 110
- Stem cells
- in acute leukemia, 262-83
 - in breast-cancer treatment, 291-92, 295, 301-2
 - bright, 361-62, 379
 - characterization of, 42-51
 - cord blood. *See* cord blood stem cells
 - cytokines in transplantation of, 53-64
 - ex vivo*, 99-103
 - gene transfer into, 79-88
 - in hematopoiesis after transplantation, 315, 319-20, 328-33
 - lymphohematopoietic, 93, 94
 - in mixed chimerism, 22
 - mouse experiments in, 20-21
 - peripheral (PSC), grafts of, 216, 218
 - peripheral blood. *See* PBSC
 - permanent genetic modification of, 102
 - purification and expansion of, 91-95
 - in vitro* growth of, 39-40
- Steroid therapy
- in GVHD, 136
 - in Hodgkin's disease, 307, 311
- Streptococcus pneumoniae*, 9
- Streptococcus pyogenes*, 9
- Streptomyces tsukubaensis*, 154
- Stroma
- biology of, 70-75
 - after BMT, 73-74
 - in cell therapy, 74, 75
- Stromal cells, 73, 74, 253-54, 378
- Succinylacetone, 150, 153, 154
- Sulfate, 179
- Supportive care, 38, 311
- SV40, 72, 82
- Syngeneic/autologous GVHD, antitumor activity of, 189-99
- T**acrolimus. *See* FK506
- TAVE protocol, 307, 310
- Taxol, 290-91, 316, 318, 325, 333
- TBI. *See* Total body irradiation
- TC 199 medium, 264
- T-cell niche, 218
- T-cell receptor (TCR), 244
- T cells, 10, 13, 38, 50, 63, 71, 92
- alloreactive
 - human cytokine-like profiles, 142
 - leukemia cells killed by, 205
 - peptidic differences and, 131 - alloresponse of, 204
 - autocytolytic, 198

- autoreactive, 189-94, 196-98
clones of, leukemia-reacting, 209
delayed add-back of, 207-8
depletion of, in GVHD, 136, 208-9, 339
memory, 213-15, 219, 221-24
original generation of, 214-15
perforin deficient, acute GVHD from, 366-67
perforin in, 205, 339-43
pre-naive, 221-22
as primary initiators of GVHD, 158
purging of. *See* purging
replacement process of, 215-20
subsets of, and cytokine production, 141-47, 190
tumors of, MRD detection of, 244
in X-linked SCID case, immune reconstitution, 376-77
- T-cell stat, 221, 223
- TC protocol, 307
- TCR (T-cell receptor), 244
- Technicon H-2 system, 352
- Terminal repeats, 80-81, 84
- Terramycin, 11
- Tetracyclines, 11
- Tetrapeptide, 63
- TGF- β (transforming growth factor), 63
- β -Thalassemia, 106
- Thalassemia major, 4, 37
- 6-Thioguanine (BACT), 4, 118
- ThioTEPA, 239, 290-91, 306-7, 316, 318
- Thoracic duct lymphocytes (TDL), 180
- Thrombocytopenia, 61
- Thy-1, 94, 353, 354, 379
- Thymidine, 208
- Thymocytes, failed engraftment of, 170
- Thymoma-agammaglobulinemia syndrome, 11
- Thymus
 children born without, 14
 "cloacal," 12
 epithelioma of, 11
 fetal, transplantation of, 146-47
 immune-system role of, 213-15
 immunodeficiency and, 11-15
 stem cells' migration to, 378
- Tissue-restricted antigens, 206
- Tissue typing, 16, 35
- TMJ protocol, 307, 309-10
- TNF (tumor necrosis factor)
 CD4 cells inhibition of leukemia through, 205
 receptor molecule family of, 253
- TNF- α (tumor necrosis factor- α), 131, 137-8, 145-46, 204
 in cytokine storm, 227-28
 as important mediator of GVHD, 230-31
 NO levels and, 232-33
- TNT regimen, 290-93, 316, 318, 333
- Total body irradiation (TBI)
 BMT and
 ABMT vs. allogeneic BMT after, 277-78
 with chemotherapy, 2, 35-36
 correction of immunodeficiency disease, 15-21
 haploidentical transplants, 20
 TBI alone, 1-2
 fractionated vs. hyperfractionated, 2
 in preparative regime for GVHD, 134
 protection from lethal doses of, 1, 34-35
- TPA (A,12-0-tetradecanoyl-phorbol-13-acetate), 144
- TQ-1, 178
- Transduction
 adeno-associated viral, 83-88, 105-11
 stem cell, 101, 102
- Trial-associated delay, 54, 55
- Trimetrexate, 153, 155-56
- Tuberculosis, 8
- Tumor cell contamination, 100-101
- Tumor necrosis factor. *See* TNF
- Tumors
 in circulating blood, 120
 detecting MRD in, 244-54
 metastatic solid, 58
 occult, 242
 purging of cells of, 102
 syngeneic/autologous GVHD vs., 189-99
 thymic, 11
- Twins, identical, 34, 131
- Two-way paradigm, 168-74
- U**
 Ultraviolet therapy in GVHD, 138-39
- Umbilical cord blood stem cells. *See* Cord blood stem cells
- United Kingdom, comparative analysis of BMT from, 203-4
- V**
 BM. *See* Vertebral body marrow
- VCAM-1 molecule, 73
- Vertebral body marrow (VBM)
 automation of isolation of, 364-65
 depletion of Class II bright cells from, 361-62
- Veto/suppressor cells, 166, 168-69
- Vimentin, 71
- Vinblastine, 306-7
- Viral vectors, 80-85
- VOD (venoocclusive disease of the liver), 38, 237-38, 240

Wiskott-Aldrich syndrome, 17, 79, 106

XLA (X-linked agammaglobulinemia),
9-11, 14

X-linked disease, 9-11, 14, 106

X-linked SCID, T-cell immune reconstitution
in, 376-77

Xomazyme, 138

Yolk sac cells for transplantation, 116

Index of Contributors

Ahmed, T., 305-314

Akhtar, T., 305-314

Annat, J., 373-377

Bacchetta, R., 141-148

Baker, M., 366-367, 368-369

Barrett, J. A., 203-212

Beer, M., 305-314

Berk, G., 305-314

Bishop, M., 242-261

Bottino, R., 364-365

Braun, S., 105-115

Brendel, M. D., 339-344

Broxmeyer, H. E., 105-115

Bruley-Rosset, M., 351-360, 373-377

Buchinger, P., 42-52

Chan, W. C., 242-261

Chao, N. J., 130-140

Chatterjee, S., 79-90

Cherry, 378

Chun, H., 305-314

Churaqui, E., 373-377

Civin, C. I., 91-98

Clark, B. R., 70-78

Coleman, M., 305-314

Cooper, S., 105-115

Dailey, T., 370-372

Day, N. K., 376-377

de La Selle, V., 351-360

De la Morena, M. T., 376-377

Deeg, H. J., 149-164

Demetris, A. J., 165-176

Donnenberg, A. D., 213-226

Donnenberg, V. S., 213-226

Dutarte, P., 373-377

Elfenbein, G. J., ix, 288-304, 315-338

Emerson, S. G., 99-104

Engelman, R. W., 380

Esquenazi, V., 345-350

Etienne-Julan, M., 105-115

Feldman, E., 305-314

Fernandez, H., 345-350

Ferrara, J. L. M., 227-236

Fields, K. K., 288-304

Fritsch, G., 42-52

Fung, J. J., 165-176

Gadner, H., 42-52

Garcia-Serra, A., 361-363

Good, R. A., 8-33, 376-377, 378, 379, 380

Gorin, N.-C., 262-287

Graham, T., 149-164

Greiner, T., 242-261

Grima, K., 305-314

Grochow, L. B., 237-241

Groux, H., 141-148

Haag, M. M., 376-377

Hall, J., 370-372

Helson, L., 305-314

Hess, A. D., 189-202

Hinds-Frey, K. R., 376-377

Hoecker, P., 42-52

Ikehara, S., 378

Inverardi, L., 339-344

Janssen, W. E., ix, 116-129, 315-338

Jones, R. J., 189-202, 237-241

Joshi, S. S., 242-261

Karatzas, T., 345-350

Katz, M., 305-314

Keating, A., 70-78

Kennedy, M. J., 189-202

Kenyon, N. S., 361-363

Kessinger, A., 242-261

Kirzner, R. P., 380

Kong, S.-S., 345-350, 364-365

Kurz, M., 42-52

Lake, D., 305-314

Leitner, A., 42-52

Levy, R. B., 339-344, 366-367, 368-369

Linetsky, E., 364-365

Lu, L., 105-115

Lu, D., 79-90

Maples, J., 370-372

Margolick, J. B., 213-226

Miller, J., 345-350

Mintz, D. H., 339-344

Mittelman, A., 305-314

Moscinski, L. C., 288-304

Murase, N., 165-176

Nelson, R. P., 376-377

Nery, J., 345-350

Niazi, Z., 305-314

Onoé, K., 379

Papish, S., 305-314

Perchick, J., 305-314
Perkins, J. B., 288-304, 315-338
Podack, E. R., 339-344, 366-367, 368-369
Podsakoff, G., 79-90
Ponnazhagan, S., 105-115
Preti, R., 305-314
Printz, D., 42-52
Puccio, C., 305-314

Qian, S., 165-176
Qian, T., 364-365

Raff, R., 149-164
Rao, A. S., 165-176
Reed, E., 242-261
Ricordi, C., 339-344, 345-350, 361-363, 364-365
Roncarolo, M.-G., 141-148
Roth, P., 379
Rouleau, M., 141-148
Ruiz, P., 345-350
Ruvolo, P. P., 189-202

Sackstein, R., ix, 177-188
Sandmaier, B. M., 149-164
Sanger, W., 242-261
Santos, G. W., 1-7
Schiff, E., 345-350
Schlegel, P. G., 130-140
Schuening, F., 149-164

Seiter, K., 305-314
Selvaggi, G., 339-344, 345-350, 364-365
Sharp, J. G., 242-261
Small, D., 91-98
Spielman, J., 339-344
Srivastava, A., 105-115
Starzl, T. E., 165-176
Stewart, F. M., 53-69
Stimpfl, M., 42-52
Storb, R., 149-164
Sutcliffe, M. J., 376-377

Tarantolo, S., 242-261
Thomas, E. D., 34-41
Thomson, A., 165-176
Traystman, M., 242-261
Tzakis, A. G., 345-350

Vogelsang, G. B., 189-202
Vose, J., 242-261

Waintraub, S., 305-314
Wang, B.-Y., 379
Wang, X.-S., 105-115
Wayne, A. S., 376-377
Webb, M., 345-350
Wong, K. K., Jr., 79-90

Xu, X.-M., 361-363

Yu, C., 149-164

